TriLink BioTechnologies, Subsidiary of Maravai LifeSciences, Expands mRNA Raw Materials Offering with First GMP-Grade Modified Nucleoside Triphosphate Product

Maravai LifeSciences Holdings LLC

TriLink now offers GMP-grade N1-methyl-pseudouridine-5′-triphosphate, an essential raw material for mRNA manufacturing, enabling researchers to accelerate their drug discovery and development timelines and source United States for their supply chain

SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) — TriLink BioTechnologies (TriLink), a Maravai LifeSciences (Maravai) (NASDAQ: MRVI) company and global provider of life science reagents and services, has expanded its offering of GMP-grade products to include N1-methyl-pseudouridine-5′-triphosphate (N1meΨTP), a modified nucleoside triphosphate (NTP) essential for the manufacture of mRNA. This new product extension leverages TriLink’s quality systems and GMP capabilities, including cleanroom manufacturing, extensive analytical testing and process verification.

The demand for N1-methyl-pseudouridine-modified mRNA has increased significantly over the past few years due to its incorporation into the two FDA-approved mRNA vaccines against COVID-19.

“A key aspect of COVID-19 mRNA vaccines is the use of a modified base, N1-methyl-pseudouridine, instead of the standard uridine base,” said Kate Broderick, Ph.D., vice -Senior President of R&D, TriLink BioTechnologies. “This modification is essential for the mRNA vaccine to work because otherwise the delicate mRNA is rapidly degraded by the immune system.”

TriLink was an early pioneer in this field as one of the first manufacturers of N1meΨTP. “Our team has been manufacturing N1-methyl-pseudouridine-5′-triphosphate for over a decade now, gaining considerable expertise,” said Jeremy Horton, senior vice president of manufacturing operations, TriLink BioTechnologies. “Our analytical capabilities for mRNA raw materials are unmatched, so it made strategic sense to apply this same level of process control to other products in our catalog. With its revolutionary CleanCap® co-transcriptional mRNA capping reagent, already available in billions of mRNA vaccine doses worldwide, the GMP grade N1-methyl-pseudouridine offering reinforces TriLink’s commitment to enabling industry to bring breakthrough mRNA-based therapies to the clinic.

“N1-methyl-pseudouridine is a key starting material for the majority of mRNA-based therapies we see in development today. Our GMP-grade N1-Methyl-Pseudouridine-5′-Triphosphate allows us to meet our customers’ domestic supply needs,” said Brian Neel, Chief Operating Officer, TriLink BioTechnologies. “We are excited to add this GMP-grade molecule to our offering of capping reagents and chemically synthesized mRNA components and consider it one of many GMP-grade reagents to come in our mRNA pipeline. “

To learn more, please visit:

About Maravai

Maravai is a leading life sciences company that provides essential products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the areas of nucleic acid synthesis and biologics safety testing to many of the world’s largest companies in the fields of biopharmaceuticals, vaccines, diagnostics and cell and gene therapy.

For more information about Maravai LifeSciences, visit

About TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO that helps life science leaders and innovators overcome the challenges of synthesizing and scaling up nucleic acids, NTPs and analogs of mRNA capping with scaling expertise and unique mRNA production capabilities, including its proprietary CleanCap® mRNA capping technology. TriLink continues to expand its cGMP and general manufacturing capability at its new global headquarters in San Diego, CA to support customers in mRNA, therapeutic oligonucleotides and plasmids, vaccines and diagnostics.

For more information about TriLink, visit

Forward-looking statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements contained in this press release that are not strictly forward-looking statements statements constitute forward-looking statements. , including without limitation statements related to the application for GMP grade N1-methyl-pseudouridine-5′-triphosphate and other nucleic acid products, constitute forward-looking statements identified by words such as “expect”, “may”, “anticipate”, or “could” and similar expressions. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, uncertainties related to the continued validation of the safety and the effectiveness of our technology, new scientific developments and the competition. from other products, and continued demand for our COVID-19 related products and services, which currently represent a significant portion of our revenues. These and other risks and uncertainties are described in more detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K, as well as in other reports filed with the Securities and Exchange Commission. the United States. Actual results may differ materially from those contemplated by these forward-looking statements and, accordingly, you should not rely on them. These forward-looking statements reflect our current views, and we undertake no obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof, except as required by law. requires it.

CONTACT: Contact Information: Media Contact: Sara Michelmore MacDougall +1 781-235-3060 [email protected] Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 [email protected]

Comments are closed.